New York, Feb 1, 2026, 10:36 EST — Market closed
- JNJ stock ended Friday near flat, closing at $227.25
- EU regulators approved broader use of the prostate cancer treatment Akeega
- Traders are eyeing Monday’s open, along with dividends and a crucial U.S. data release due later this week
Johnson & Johnson (JNJ.N) shares closed Friday nearly flat, slipping just 0.01% to $227.25. The stock moves into Monday following a positive nod from European Medicines Agency advisers, who supported expanding the use of its prostate-cancer drug Akeega. (European Medicines Agency (EMA))
Why it matters now: Johnson & Johnson is relying on oncology and newer specialty drugs to sustain growth as its older blockbusters decline and policy risks mount. On Jan. 21, the company projected 2026 sales between $99.5 billion and $100.5 billion, with adjusted earnings of $11.43 to $11.63 per share. It also warned of tariff pressures and the impact of a U.S. prescription-drug pricing deal. (Reuters)
Europe plays a major role in that strategy. Expanding a label can unlock a broader patient base, but it often means navigating a lengthy slog of regulatory reviews, pricing negotiations, and reimbursement hurdles.
The Committee for Medicinal Products for Human Use has recommended broadening Akeega’s approval to include metastatic hormone-sensitive prostate cancer in patients carrying BRCA1/2 mutations. The final call now rests with the European Commission.
Johnson & Johnson said the recommendation applies to Akeega, a dual-action pill that pairs niraparib with abiraterone acetate, used alongside hormone-blocking therapy. Henar Hevia noted that patients with BRCA mutations often face “more aggressive disease” and have fewer treatment options before the cancer becomes tougher to manage. The company highlighted a Phase 3 trial showing a 48% reduction in the risk of cancer progression or death in this BRCA subgroup. Charles Drake described the development as a move toward “integrating targeted precision medicine into routine care.” (Jnj)
Akeega employs a PARP inhibitor, a drug that blocks a DNA-repair enzyme, stepping into the crowded prostate-cancer field where precision medicines are stacking up. AstraZeneca and Pfizer also offer cancer therapies that investors keep a close eye on whenever the market starts buzzing about the “next growth driver.”
Analyst buzz pushed the stock up. On Friday, HSBC lifted its price target from $240 to $265 and kept a buy rating, MT Newswires reports. (MarketScreener)
At this stage, every detail counts. When JNJ hits near its highs, even a slight change in growth forecasts, a snippet from the pipeline, or a new legal issue can shift the stock beyond what the day’s volume shows.
But risks remain. A CHMP opinion doesn’t guarantee sales approval, and the final decision could drag on. Usual concerns like U.S. drug-pricing changes and litigation expenses still weigh on the stock, despite its recent stability.
Investors chasing income should note a key date: J&J’s next quarterly dividend will go ex-dividend on Feb. 24. Anyone buying shares after that won’t get the dividend set for March 10. (Jnj)
Friday’s U.S. jobs report, set for Feb. 6 at 8:30 a.m. EST, is the key market catalyst next week. The data could shift rate expectations and move defensive areas like healthcare. (Bls)
